Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MEASURE 2
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 04 Jun 2022 Results of post-hoc analysis evaluating key clinical symptoms at baseline through Wk 260, presented at the 23rd Annual Congress of the European League Against Rheumatism
  • 01 Feb 2022 Results of post-hoc pooled analysis of 3 secukinumab studies (MEASURE 2,-3 &-4) assessing -term NSAID-sparing effect of secukinumab over 4 years in patients with r-axSpA, published in the Rheumatology International.
  • 09 Nov 2021 Results of pooled post-hoc analysis assessing efficacy of secukinumab in patients with oligoarticular PsA by using data from five phase III studies presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top